CytoMed, Stiefel deal

Under an exclusive agreement, Stiefel will develop and register CMI-392 for dermatologic use in Europe, Latin America, Canada, Australia, New Zealand and other countries. CytoMed could receive up to $11 million in equity investments, fees and milestones, excluding royalties. ...